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Growing evidence suggests that control of hematopoiesis is one of the functions 
exerted in vivo by natural killer (NK)~cells (1), and cells with NK cell character- 
istics  have  been  shown  to  inhibit different types of hematopoietic colonies  in 
vitro (2, 3). We have shown (4) that the human peripheral blood cells responsible 
for this inhibition bear the surface markers of cytotoxic NK cells, and that this 
inhibitory effect is mediated by a soluble factor, NK cell-derived colony-inhibit- 
ing activity (NK-CIA), released by NK cells upon culture with NK-sensitive target 
cell lines, or with bone marrow cells. A soluble factor, the NK-derived cytotoxic 
factor (NKCF) (5), might mediate the cytotoxic effect of NK cells. Like NK-CIA, 
NKCF is released by lymphocytes cultured with NK-sensitive target cells.  The 
sensitivity  of different  cell  lines  to  the  cytotoxic  effect  of NKCF  correlates 
generally with  their sensitivity to  NK cell-mediated cytotoxicity (6),  although 
some cell  lines are  sensitive to  NKCF but not to  NK  cell cytotoxicity because 
they fail to induce NKCF production by NK cells, whereas other cell lines induce 
NKCF but are  not sensitive to it (7).  Interferon (IFN)-treated  target cells, for 
example,  are  much  less  susceptible  to  NK  cell-mediated cytotoxicity (8),'and 
they do not induce NKCF production (7);  on the other hand, IFN enhances the 
cytotoxicity of NKCF (7).  Based on these observations,  two recognition events 
to allow NK  killing have been  proposed:  the first allows binding of NK to the 
target cells, and the second allows the release of NKCF (7, 9).  The relationship 
of NKCF with other lymphotoxins (LT) produced by T  cells upon antigen- or 
lectin-stimulation has not been completely clarified (10).  The enhancing effect 
of IFN on  NKCF activity, reminiscent of the phenomenon described  with LT 
(1 1),  and  the  fact that some anti-LT antisera  partially inhibit  NK killing (10), 
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suggest a similarity between LT and NKCF; however, preliminary biochemical 
characterization of NKCF (12)  seems to exclude its complete identity with LT, 
at least on the basis  of molecular weight. The genes encoding LT and tumor 
necrosis factor (TNF), a cytotoxic factor produced mostly by monocyte/macro- 
phages and with amino acid sequence homology with LT, have been  recently 
cloned (13-15).  Monoclonai antibodies (mAb) specific for LT (13) and TNF are 
now available, making possible a  more accurate analysis of the relationship of 
NKCF and NK-CIA with LT and TNF. 
Various soluble factors produced by leukocytes have been described that inhibit 
bone marrow colony formation. Various types of IFN (16, 17) and prostaglandins 
(18)  have proved to be effective inhibitors of various types of colonies. An 80 
kilodalton (kD) molecule with high inhibitory activity on hematopoietic precursor 
cells and toxicity on HLA-DR  + cell lines has been recently described (19) that is 
produced by a  hybrid between peripheral blood T  ceils and the Jurkat T  cell 
line.  Other  factors,  such  as  lactoferrin or  acidic isoferritin, are  produced  by 
normal or leukemic cells, and inhibit hematopoietic colonies mostly by blocking 
production of colony-stimulating factors (CSF) by macrophages (20, 21). 
In the present study, we analyzed the relationship of NK-CIA with NKCF and 
IFN and show that NKCF and the factor responsible for NK-CIA are simulta- 
neously  produced  by  NK  cells,  and  appear  indistinguishable  in  a  series  of 
functional and biochemical analyses. IFN do not account for NK-CIA activity, 
but recombinant IFN-3, acts synergistically with NK-CIA, reversing the normal 
resistance of late GM precursor cells to NK-CIA. mAb against TNF but not LT 
completely block  both  NKCF  and  NK-CIA  activity,  and  recombinant  TNF 
mediates both NKCF and NK-CIA activity. 
Materials and Methods 
Cell Lines.  The human erythromyeloid leukemic cell line K562, the macropbage line 
U937, the B cell line Raji, the Detroit 539 fibroblast, and the murine P815y mastocytoma, 
and L929 cells of the c~ subline were maintained in culture in RPMI 1640 medium (Flow 
Laboratories,  Inc.,  Rockville, MD) supplemented  with  10%  fetal  bovine  serum  (FBS) 
(Flow Laboratories,  Inc.). All cell lines used were repeatedly tested and constantly found 
free of mycoplasma contamination by Hoechst fluorescent staining for cytoplasmic DNA, 
and by direct anaerobic agar plate cultivation. 
Monoclonal  Antibodies.  Antibody B73.1 (IgG1) reacts  with the receptor for the  Fc 
fragment of IgG present  on human NK cells and neutrophilic  granulocytes, and detects 
virtually all resting and IFN-induced  NK cells (22, 23). B36. I (IgG2b) reacts with the 69 
kD surface  molecule  (T1  antigen)  present  on all peripheral  blood T  cells (23). These 
antibodies, and the anti-HLA-DR common determinant antibody B33.1 (IgG2a) (23, 24) 
have all been produced in our laboratory.  The anti-NK antibody N901 (IgG1) (25) was 
kindly provided by Dr. J. Griffin (Dana-Farber Cancer Institute, Boston, MA). Superna- 
tants from the hybrid cell lines were used throughout this study. 
Peripheral  Blood  Lymphocytes (PBL) and  PBL  Subpopulations.  Peripheral blood  was 
obtained by venipuncture from healthy donors, and anticoagulated with preservative-free 
heparin.  Mononuclear  cells were  prepared  by  density  gradient  centrifugation  on  Fi- 
coll/Hypaque (F/H) (1.077  _.+ 0.01 g/ml),  and depleted of monocytes by adherence to 
plastic for 45  min at 37°C.  PBL subpopulations  were obtained  by indirect  rosetting of 
antibody-sensitized  PBL with CrCl3-treated, anti-mouse Ig-coated sheep erythrocytes, 
according to our previously described  technique  (22, 24). The goat F(ab')2 anti-mouse 
Ig (Cappet Laboratories,  Cochranville,  PA) used was preabsorbed  with human Ig and 
immunopurified on a mouse lg-CNBr-Sepharose (Pharmacia Fine Chemicals, Uppsala, 1514  NATURAL  KILLER CELL-DERIVED COI~ONY-INHIBITING FACTOR 
Sweden)  column,  as  described  (22).  Both  antibody-positive  (rosetting)  and  -negative 
(nonrosetting) populations were recovered after F/H density gradient centrifugation, and 
contaminating erythrocytes were lysed hypotonically. 
Bone Marrow Cell Preparations.  Rib bone marrow cells were purified from specimens 
(kindly  provided  by  Dr.  P.  Addonizio,  Dept.  of Surgery,  University  of Pennsylvania, 
Philadelphia,  PA) that are routinely removed during thoracic surgery. The marrow was 
collected in sterile RPMI 1640 with  10% FBS, sequentially flushed with medium through 
18-,  23-, and  27-gauge needles,  and  the  cell  suspension  was layered on a  F/H  density 
gradient  (1.077  g/ml).  Mononuclear cells  collected at  the  interface  were washed three 
times with RPMI  1640 supplemented  with  10%  FBS.  In the indicated experiments,  the 
mononuclear cells were depleted of mature  monocytes and other adherent  cells by two 
cycles of adherence  to plastic  surfaces.  The resulting population was further  separated 
into  HLA-DR  +  and  HLA-DR-  cells  by  indirect  rosetting  (as  described  above),  after 
sensitizing the cells with mAb B33.1. ~10-15% of the bone marrow cells were recovered 
in the HLA-DR  + fraction, which contained virtually all colony-forming units of granulo- 
cytes and macrophages (CFU-GM). 
Bone Marrow Colonies.  The CFU-GM assay was performed according to the method 
of Pike and Robinson (26), with slight modification. Medium conditioned by the Detroit 
554 cell line (kindly provided by Dr. R. K. Shadduck, Montefiore Hospital, University of 
Pittsburgh  School of Medicine,  Pittsburgh,  PA) was used as a source of CSF (26).  Bone 
marrow  cells  were  resuspended  (10 "~  cells/ml)  in  0.3%  agar  (Difco  Laboratories,  Inc., 
Detroit, MI) in supplemented McCoy's medium (Gibco Laboratories, Grand Island, NY), 
containing  10%  Detroit  cell-conditioned  medium.  1-ml aliquots of the  cell suspension 
were  seeded  into  35-mm  Petri  culture  dishes  (Lux  Plastics,  Flow  Laboratories,  Inc., 
McLean, VA), and cultured at 37°C in a 5% CO2 humidified atmosphere in air. Colonies 
(aggregates containing >50 cells) were scored on days 7 and 14 of culture. Colony growth 
on day 7 evaluates differentiation  and proliferation of more mature GM precursor cells 
(late CFU-GM), colony growth on day  14 evaluates  these parameters  in more primitive 
cells (early CFU-GM) (27). All cultures were performed in triplicate. The results of CFU- 
GM are expressed as number of colonies per  105 plated cells.  The same lots of FBS and 
Detroit cell-conditioned medium were used throughout. 
Production  of Supernatant Fluids from PBL Cocultured with Cell Lines or with Bone Marrow 
Cells.  PBL and the different PBL subpopulations were resuspended  (5  x  106 cells/ml) 
in RPMI  1640 with 10% FBS, but with or without 103 U/ml partially purified IFN-a (10 6 
U/mg; Interferon Sciences, New Brunswick, NJ) and incubated for 18 h at 37°C in a 5% 
CO., humidified atmosphere in tissue culture flasks (Falcon Labware, Oxnard, CA). After 
culture, the cells were washed three times with phosphate-buffered saline (PBS, pH 7.2), 
and resuspended  (3  ×  10 6 cel[s/ml) in  RPMI with  10%  FBS containing K562,  Raji,  or 
P815y cells (6  X  10 '~ cells/ml  final  concentration).  After a  6-h incubation at  37°C,  the 
cells were centrifuged,  and cell-free supernatants  were harvested.  Control supernatants 
were prepared  using either effector or target cells alone under the same experimental 
conditions as above.  In the indicated experiments,  supernatants  were obtained using as 
inducer total mononuclear bone marrow cells, nonadherent mononuclear bone marrow 
cells, or HLA-DR  + and HLA-DR- bone marrow subpopulations (3  x  l0 s cells/ml,  final 
concentration). Supernatants were either used immediately, or kept frozen at -70 °C until 
used. The effect of soluble factors on colony formation was tested by adding supernatants 
(100 ~1 or the indicated quantities) at the time of addition of the bone marrow cells, or at 
the indicated time after seeding to triplicate dishes. 
[:~H]Thymidine (['SH]TdR)  Incorporation.  Cell  lines (Raji,  U937) were resuspended  in 
RPMI with  10%  FBS supplemented or not with different concentrations of recombinant 
TNF  (rTNF).  200  #1  of the  cell  suspension  were  plated  in  each  well  of flat-bottomed 
microtiter  tissue  culture  plates  (5  x  103  cells/well)  and  cultured  for 4  d  at  37°C.  6  h 
before harvesting, the cells were pulsed with [3H]TdR (sp act, 2 Ci/mmol; New England 
Nuclear, Boston, MA), at 2/~Ci/well.  The cells were collected on glass-fiber filters using 
an automatic cell harvester  (Skatron Co., Sterling,  VA), and cell-incorporated [~H]TdR 
was assayed by liquid scintillation counting. DEGLIANTONI  ET  AL.  1515 
Assay for NKCF.  NKCF in  the  supernatants  was tested  in an  18-h ~lCr-release  assay 
using several different target cells, as indicated.  Different concentrations of supernatant 
were added to 51Cr-labeled target cells (U937,  2.5 x  l0 s cells/well;  K562 and the other 
cell lines,  5  x  l0 s cells/well) in  100 #1 final volume, in triplicate  wells of flat-bottomed 
microtiter plates.  After an  18-h incubation,  100 ~1 of PBS were added to each well, and 
100 #1 of supernatant  were collected after spinning.  Percent specific 5~Cr release =  100 
x  [(cpm released  from experimental  samples)  -  (spontaneous cpm released  from target 
cells alone)]/[(maximum cpm released from target cells with Triton X-100) -  (spontaneous 
release)]. 
NK  Cytotoxicity Test.  This  was  performed  as  previously  described  (28)  using  5~Cr- 
labeled K562 cells (104  cells/well) as targets in a  3-h assay. Cytotoxicity was quantitated 
from the  cytotoxicity curves  obtained  using at  least  four different  effector/target  cell 
ratios, in terms of lytic units, calculated using a modified von Krogh equation, as described 
(29).  One lytic unit is defined as the number of effector cells required  to mediate  45% 
specific "~Cr release from the target cells during the assay period. 
Absorption  of Supernatants with Different  Cell Types.  Cell-free supernatants  were incu- 
bated with the indicated cell lines or bone marrow cell populations (5 x  106 cells/mi) for 
6  h  at  20°C  with  intermittent  shaking.  Cell-free  supernatant  was then  harvested after 
spinning the cells (2,000 rpm for 5  rain).  D-Mannose-6-phosphate (Sigma Chemical Co., 
St.  Louis, MO) was dissolved in RPMI  1640 supplemented with  10% FBS, and used at a 
final concentration of 25 or 50 mM in assays of NKCF and NK-CIA activity and absorption. 
Supernatants  produced  or  absorbed  in  the  presence  of D-mannose-6-phosphate  were 
dialyzed for  18  h  at  4°C against  RPMI  1640  and  sterilized  by  20,000  rad  irradiation 
before use. 
Chromatographic Fractionation  of NK-CIA-containing Supernatants.  NK-CIA-containing 
supernatant  was prepared  from  IFN-c~ (10 s  U/ml  per  5  ×  10  6  cells)-stimulated  B73.1 ÷ 
PBL cultured with K562 cells as inducers. All stimulations were performed in RPMI 1640 
supplemented  with  1%  FBS.  The cell-free  supernatant  was concentrated  50-fold by an 
Amicon Model 8050 stirred cell equipped with a PM-10 membrane, and fractionated by 
gel filtration chromatography using a fast protein liquid chromatography (FPLC) system 
(Pharmacia Fine Chemicals) with a Superose 12 column. Samples (200 #1) were applied to 
the column and eluted with 0.1% polyethylene glycol 8000, 0.1  M/3-lactose, and 0.1 mM 
phenylmethylsulfonyl fluoride in PBS, pH 7.4, at a flow rate of 0.6 ml/min.  Fractions of 
500 ~1 were collected, dialyzed against medium, and sterilized by filtration. Alternatively, 
the samples were dialyzed against 20 mM Tris buffer, pH 7.8, and applied to a Mono Q 
anion-exchange column (Pharmacia Fine Chemicals). The column was eluted with a linear 
gradient  of 0-1  M  NaC1  in  20 mM  Tris buffer, pH  7.8,  at a  flow rate of 0.8  ml/min. 
Fractions of 1 ml were collected, dialyzed, and sterile-filtered as above. 
Lymphokines and Antilymphokine  Antibodies.  Human recombinant IFN-y (rIFNs') from 
E. coli was kindly provided by Drs. J. C. Sevastopoulos and  H. M.  Shepard (Genentech, 
Inc., South San Francisco, CA) and has a antiviral activity titer of 7 x  107 U/mg on HeLa 
cells. No significant CSF activity was demonstrable in the rIFN-3, preparation using normal 
bone marrow cells. Recombinant type A  IFN-a (rIFNA) from E. coli (2 X  l0 s U/mg) was 
kindly  provided  by  Hoffman-LaRoche,  Inc.  (Nutley,  NJ).  Purified  human  IFN-y (106 
U/rag) was obtained from Interferon Sciences, Inc. (New Brunswick, NJ). Human rIFN- 
/3 (sp act,  1.5 X  10  s U/rag) and human rTNF (90% pure,  10  v U/mg on L-929 cells)  were 
kindly provided by Dr. J. S. Price (Cetus Corp., Emeryville, CA). Sheep antiserum against 
human  IFN-c~  (105  neutralizing  U/ml)  was  obtained  from  Interferon  Sciences.  mAb 
B133.3 (IgG1), which reacts specifically with human IFN-~, and with neither IFN-e~ nor - 
/3 (30), was used as ascites; it had a titer of 1.5 x  l0 T neutralizing U/ml. mAb specific for 
human LT (LTB) (5.5 X 102 inhibiting U/mg antibody) and to human TNF (TNFD) (2.7 
x  10 s inhibiting U/~g antibody) were kindly provided by Dr. H. M. Shepard (Genentech, 
Inc.) and used at a final concentration of 5 ug/ml to pretreat (6 h at 4°C) NKCF- or NK- 
CIA-containing supernatant. 
Assay of Cytotoxins on L Cells.  The cytotoxic activity of the supernatants on mouse L- 
929 cells (a subline) was assayed in flat-bottomed 96-well microtiter plates by adding serial 1516  NATURAL  KILLER  CELL-DERIVED  COLONY-INHIBITING  FACTOR 
dilutions of supernatant fluid to 4 ×  104 L cells/well in the presence of 1 #g/ml actinomycin 
D  (Calbiochem Behring Corp.,  La Jolla,  CA).  Cytotoxicity was  scored microscopically 
after incubation for 24 h  at  37°C.  1 U  of cytotoxin is defined as  the highest dilution 
producing 50% cytotoxicity. 
IFN Test.  Antiviral activity in  the supernatants was tested by inhibition of the cyto- 
pathic effect of vesicular stomatitis virus (VSV) on human fibroblast strain Detroit 539, 
derived from a subject with trisomy 21. The IFN concentration inducing 50% protection 
fi'om the cytopathic effect on Detroit cells corresponded to ~1 U of the National Institutes 
of Health (NIH) IFN-~, standard Gg-23-901-530 and to 0.1  U of the NIH IFN-a standard 
G-023-901-527. 
Results 
Correlation  Between Production  of NK-CIA  and NKCF.  NKCF activity, as de- 
tected in  an  18-h  "~Cr-release assay on the  NK-sensitive  K562  or U037  target 
cell line,  was  present  in  the  cell-free supernatant  fluid containing  NK-CIA.  A 
highly significant positive correlation between  cytotoxic activity on  U037  cells 
and inhibition of CFU-GM was seen (Fig.  1) at  14 d  in 32 different supernatant 
fluids  produced  by  various  PBL  subsets  from  different  donors  stimulated  by 
culture with  K562 cells.  Different PBL subsets, separated  by indirect rosetting 
using various  mAb,  were  tested  for cell-mediated cytotoxicity on  K562  target 
cells and  for their ability to produce  NKCF and  NK-CIA  when  cultured  with 
K562 cells. Table I gives the results obtained with some of the antibodies tested. 
NK activity and production of both NKCF and  NK-CIA segregate in the same 
PBL subset, i.e., B73.1/N901 +, and B36.1/B33.1- (Table I). Like cytotoxic NK 
cells, a proportion of both NKCF and NK-CIA-producing PBL reacted with anti- 
T8 antibody B 116.1 and with antibody HNK-1, whereas PBL reacting with anti- 
T4 antibody B66.6 and with OKT3  never produced either factor (not shown). 
Production of both  NKCF and  NK-CIA  (Table  I), as  well as  NK activity (not 
shown), are increased upon IFN-c~  treatment of the PBL subsets containing NK 
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FIGURE  1.  Correlation  between  NKCF and  NK-CIA.  Different supernatants, obtained  by 
induction of various PBL subsets from different donors with K562 cells, were simultaneously 
tested for NKCF activity (SJCr release from U937 target cells, incubated in a final supernatant 
concentration of 50%) or for NK-C1A (100/~1 supernatant per dish). Each dot represents the 
values obtained with  a  separate supernatant. DEGLIANTONI  ET  AL.  1517 
TABLE  I 
Cell-mediated NK Activity and K562-induced Production of 
NKCF and NK-CIA by PBL Subsets 
Exp. 
NK 
(lytic units  NKCF  NK-CIA 
PBL subset*  per 107  (percent 5~Cr release)  0  (percent inhibition)  | 
cells)* 
PBL  PBL  IFN-PBL  PBL  IFN-PBL 
Unseparated  78,9  16.9  25.1  36.8  52.3 
B73.1 +  659,7  33.2  42.6  59.9  81.2 
B73.1-  3.9  2.5  2.8  14.9  17.8 
Unseparated  37.3  29.4  51.5  33.8  46.9 
B36.1 ÷  1.3  1.2  2.3  2.3  6.7 
B36.1-  326.5  74.5  87.7  54.5  68.3 
B33.1 +  1.2  2.3  3.0  0.9  3.9 
B33.1-  28.3  45.2  56.5  31.1  44.5 
N901 ÷  276.8  68.6  88.5  63.4  72.8 
N901-  0.2  3.4  9.3  1.7  5.6 
PBL or PBL subsets were incubated for 18 h at 37 °C in the presence (IFN-PBL) or absence (PBL) 
or  1,000  U/ml of IFN-a before coculture with K562 cells.  Data are average of results obtained 
with two donors. 
* PBL subsets were separated by indirect rosetting after sensitization with the indicated mAb. 
* NK activity was tested in cell-mediated cytotoxicity assay on K562 target cells. 
§ NKCF activity, induced during 6-h culture with K562 cells, was tested on K562 cells (Exp.  1) or 
U937 cells (Exp. 2) (50% supernatant final concentration). 
II NK-C1A,  induced during 6-h culture with K562 cells, was tested for inhibition of 14-day (early) 
CFU-GM (100 ~1 supernatant per dish). 
TABLE  II 
Production  of NKCF and NK-CIA Induced by Different Cell Types 
B73.1 + PBL cocultured with 
inducer cells 
NK-CIA  NKCF  (percent CFU-GM [early] 
(percent ~lCr release)  inhibition) 
PBL  IFN-PBL  PBL  1FN-PBL 
None  1.3,  1.0  2,0, 2.0  -4.5, 0.0  -3.0, 3.1 
K562  28.8, 29.0  37.7, 41.0  47.0, 63.7  63.7, 78.8 
Raji  0.7, 0.0  1.0, 0.0  0.0, 0.0  0.0, 0.6 
Bone marrow, HLA-DR  ÷  34.7, 38.5  51.7, 47.9  41.9, 43.9  55.2, 56.2 
Bone marrow, HLA-DR-  5.6, 2.8  5.4, 4.8  6.2, 4.1  7.2, 2.1 
Following coculture for 6 h at 37°C with the indicated inducer cells, supernatants were assayed for 
NKCF (U937 target cells, final supernatant concentration 50%) or for NK-CIA (100 #1 supernatant 
per dish).  B73.1 ÷ producer  PBL were incubated for  18 h  at 37°C  in the presence (IFN-PBL) or 
absence (PBL) of 1,000 U/ml of IFN-c~ before coculture with inducer cells. Data are given separately 
for two independent experiments. 
cells,  but  the  same  treatment  does  not  induce  production  of either  lymphokine 
by the  NK  cell-depleted  PBL  subsets. 
The  ability of different  cell lines and  bone  marrow  cells to induce  NKCF  and 
NK-CIA  production  was tested  using  PBL  preincubated  or not with IFN-a.  Total 
(not  shown)  and  B73.1 +  PBL  (Table  II)  produced  both  NKCF  and  NK-CIA 
when  cultured  with  the  NK-sensitive  target  cells  K562  or  with  HLA-DR  +  bone 1518  NATURAL  KILLER  CELL-DERIVED  COLONY-INHIBITING  FACTOR 
TABLE  III 
Absorption of NK-CIA and NKCF by Different Cell Types 
NKCF  NK-CIA 
Absorbing cells  (percent 5JCr release  (percent CFU-GM [early] 
[U937])  inhibition) 
None, -70°C  53.7, 70.2  62.8, 45.7 
None, 6 h at 20°C  50.2, 67.1  62.8, 47.4 
K562  19.6, 27.6 (59.8)  2.8, 8.8 (89.5) 
Raji  53.2, 66.5 (-1.0)  61.1, 49.2 (0) 
Bone marrow, nonadherent  23.1, 22.9 (60.8)  27.4,  19.3 (57.7) 
Bone marrow, HLA-DR  +  23.0,  16.8 (66.1)  12.7,  12.3 (77.4) 
Bone marrow, HLA-DR-  46.4, 49.4 (18.3)  62.8, 47.4 (0) 
Two  preparations  of NK-CIA-containing supernatants  (produced  by  IFN-c~-treated  B73.1 ÷  PBL 
induced by K562 cells) were tested for NKCF (50% supernatant  final dilution) and NK-C1A (100 #1 
supernatant per dish) as described, immediately after defrosting (-70°C) or after absorption for 6 h 
at 20°C (5 x  106 cells/ml) with the indicated cell types. Data are given separately for two independent 
experiments. Numbers in parentheses are average percent absorptions compared to the control kept 
for 6 h at 20°C. 
marrow cells, and the production was enhanced by preincubation of PBL with 
IFN-a.  PBL, pretreated or not with IFN-~,  produced neither  NKCF nor NK- 
CIA when cultured alone or in the presence of NK-insensitive Raji cells, or with 
HLA-DR- bone marrow cells. B73.1-  PBL did not produce NKCF or NK-CIA 
in response to any of the tested inducer cells, regardless of IFN-a pretreatment 
(not shown). 
Absorption  of NK-CIA and NKCF on Cell Lines and on Bone Marrow Cells.  The 
ability of different cell types to absorb NK-CIA and NKCF was then tested. Bone 
marrow and K562,  but not Raji cells, absorb  most of the NK-CIA and  NKCF 
activity from  the  supernatants  in  6  h  at  20°C  (Table  III).  Among  the  bone 
marrow cells, only HLA-DR  + cells were able to absorb both NK-CIA and NKCF, 
whereas HLA-DR- cells did not absorb either activity significantly. When total 
bone  marrow or  HLA-DR  + ceils were washed after the absorption and plated 
for colony formation, inhibition of 14-d CFU-GM was observed (not shown). 
Ability  of D-Mannose-6-phosphate  to Block Both NK-CIA and NKCF Activity  and 
their Absorption  by Target Cells.  As previously reported (31)  for several  mono- 
saccharides,  D-mannose-6-phosphate  inhibited  the  NKCF  cytotoxic  effect  on 
U937  cells  when  present  during  the  5~Cr-release  assay.  The  inhibition  was 
complete at a 50 mM concentration of D-mannose-6-phosphate, and partial at 25 
mM (Fig. 2). Addition of the sugar at these two concentrations during the CFU- 
GM assay did not affect colony formation, but prevented the inhibition of early 
CFU-GM  by  NK-CIA.  An  almost  complete  reversion  of the  inhibition  was 
observed when D-mannose-6-phosphate was used at a 50 mM concentration, and 
a  partial reversion resulted when a  25 mM concentration was used (Fig. 2). To 
test  whether  the  sugar  inhibited  binding  of the  factors  to  the  target  cells,  a 
supernatant produced by IFN-~-pretreated B73.1 + cells cultured with K562 ceils 
was absorbed on K562 cells in the presence or absence of 50 mM D-mannose-6- 
phosphate, dialyzed to eliminate the sugar, and tested for residual NK-CIA and 
NKCF  activity  (Fig.  3).  Addition  of  50  mM  D-mannose-6-phosphate  to  the 
supernatant, followed by dialysis, did not alter NK-CIA and NKCF activity. The DEGLIANTONI  ET  AL.  1519 
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FIGURE 3.  D-Mannose-6-phosphate inhibits absorption of NKCF and NK-CIA to K562 cells. 
Supernatant fluid from I FN-a-pretreated B73.1 + PBL induced by K562 cells was absorbed on 
K562 cells in the presence or absence of 50 mM D-mannose-6-phosphate,  and tested, at the 
indicated quantity per assay, for (A) NKCF activity (U937 target cells) or (B) NK-CIA activity. 
(0),  unabsorbed  supernatant;  (&), supernatant  absorbed on  K562  cells;  (©), unabsorbed 
supernatant to which  50 mM  D-mannose-6-phosphate was added; (A), supernatant absorbed 
on  K562  cells  in  the  presence of 50  mM  D-mannose-6-phosphate.  All supernatants  were 
dialyzed against  RPMI  1640  medium  before testing in  order  to  eliminate D-mannose-6- 
phosphate. 
presence  of the  sugar,  however,  completely prevented  absorption  of both  NK- 
CIA and  NKCF  activity on  K562  cells. 
Interaction  Between NK-CIA  and IFN.  The  presence  of IFN  in  the  NK-CIA- 
containing supernatants was tested by inhibition of the cytopathic effect of VSV 
on  human  fibroblasts.  No detectable IFN  (<1  U)  was ever found  in the  super- 
natants produced  by untreated  PBL, whereas titers of IFN  up to  10  U/ml  were 
occasionally found in supernatants produced  by PBL pretreated  with IFN-o~ (not 
shown). The  antiviral activity detected in these supernatants was partially blocked 
by  either  a  sheep  antiserum  to  IFN-o~ or  by  an  anti-IFN-~,  mAb,  and  it  was 
completely inhibited by a  mixture  of the two antibodies.  To  test the possibility 1520  NATURAL  KILLER  CELL-DERIVED  COLONY-INHIBITING  FACTOR 
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FIGURE 4.  Inability of anti-IFN antibodies to suppress the activity of NKCF and NK-CIA. 
Supernatant fluid from IFN-~-pretreated B73.1 + PBL induced by K562 cells was tested, at 
the indicated quantity per assay,  for (A) NKCF activity (U937  target cells) or (B)  NK-CIA 
activity in  the presence or absence of rIFNy  or  various anti-IFN antibodies.  Assays  were 
performed in: (O),  medium alone; (O),  1,000  U/mI rlFNy;  (A), sheep anti-IFN-c~ antiserum 
(10  -2 final dilution); (&), B133.3 anti-IFN-y mAb (ascites 10  -3 final dilution); (lZ]), anti-IFN-a 
and anti-lFN-'y antibodies. 
that IFN play a role in either the NKCF or NK-CIA activity of the supernatants, 
the ability of anti-IFN antibodies to affect NKCF or NK-CIA activity was tested. 
Results of one representative experiment out of three performed with identical 
results are shown in Fig. 4.  NKCF or NK-CIA activity was not affected by the 
anti-IFN-~  antiserum,  by  the  anti-IFN-y  mAb,  or  by  a  mixture  of the  two 
antibodies during the assay. Addition of rlFN-3, during the assay had an additive 
effect on the inhibition of CFU-GM (early) growth by NK-CIA and, like IFN-~ 
(not shown), had a synergistic effect on the cytotoxicity of NKCF on U937 cells. 
The effect of simultaneous addition of IFN and NK-CIA-containing superna- 
rants on early (14-d) and late (7-d) CFU-GM formation by bone marrow cells was 
tested in three separate experiments. Representative results are reported in Fig. 
5.  Homogenous preparations of rlFN-~, -/3 or -3' were added to the culture, in 
the presence  or absence of supernatant fluid of B73.1 + cells (not  IFN-oe-pre- 
treated) cultured with K562 cells.  No antiviral activity was detectable in the NK- 
CIA-containing supernatant.  Both  rlFN-o~  and -/3 alone each  induced a  dose- 
dependent inhibition of CFU-GM, which was more apparent on day 7 than on 
day  14  colonies.  <1,000  antiviral  U/ml  of rlFN-3,  did  not  inhibit  or  only 
moderately inhibited CFU-GM. The NK-CIA-containing supernatant alone did 
not inhibit day 7 colonies, and inhibited day 14 colonies by ~50%. When rlFN- 
ot and -/3 were added to NK-CIA, the degree of inhibition of day 7 colonies was 
the same as that observed using the two IFN types alone; rlFN-~ and -/3 and NK- 
CIA had a  less  than additive effect on  day  14  colonies. On  the contrary, the 
simultaneous presence of rlFN-3, and NK-CIA resulted in a dramatic synergistic 
inhibition of day 7  CFU-GM, and almost complete inhibition of colonies was 
obtained with  1,000  U/ml rlFN-%  This synergistic effect was  still  present on DEGLIANTONI  ET AL.  1521 
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FIGURE 5.  Effect of simultaneous addition of IFN and NK-CIA to CFU-GM colonies, Normal 
bone marrow cells were plated in the presence or absence of the indicated IFN types and NK- 
CIA-containing supernatant  (supernatant of B73.1  + PBL induced by K562 cells). Colonies 
were scored on day 7 (late CFU-GM) and on day 14 (early CFU-GM). (O), cultures in medium 
only; (O) cultures to which 100 #l/dish of NK-C1A-containing  supernatant was added. 
day  14  CFU-GM,  but  it was  masked  in  part  by the effective inhibition  due  to 
NK-CIA alone. 
Fractionation of  NK-CIA and NKCF-containing Supernatant Fluid by Gel Filtration 
and Anion-exchange  Chromatography.  The  NKCF  and  NK-CIA-containing  su- 
pernatants  contained <1-8  U  of cytotoxin when assayed on L-929 target cells 
(results  not  shown).  When  the  supernatant  fluids  were  fractionated  on  gel 
filtration  columns  using  an  FPLC  apparatus,  NKCF  (U937  target  cells)  and 
cytotoxin (L-929 target cells) activities coeluted in a broad peak between  15 and 
40 kD, which resolved in most experiments as two partially overlapping peaks of 
15-20  and  30-35  kD  (Fig.  6).  NK-CIA activity also eluted in  the same  broad 
peak (results not shown). NKCF and cytotoxin activities were also coeluted from 
a  Mono Q  column at ~0.15  M  NaCI (Fig. 6). 
Effect of Anti-LT and Anti-TNF mAb on NKCF and NK-CIA Activity.  Six differ- 
ent supernatant fluids obtained by incubation of NK cell-enriched preparations 
with K562 cells, and four obtained by incubation with allogeneic bone marrow 
cells were incubated  for 6  h  at  4°C  in  the presence of 5  #g/ml  of LTB or of 
TNFD, then tested for NKCF activity on U937 cells and for NK-CIA activity on 
early and  late CFU-GM,  in  the presence or absence of 1,000  U/ml  of rIFN-3~ 
(Table IV). In all cases, the anti-TNF antibody completely abolished NKCF and 
NK-CIA activity, whereas the anti-LT antibody had no effect. 
NKCF and NK-CIA Activity Mediated by rTNF.  rTNF in concentrations ranging 
from  0.06  to  64  U/ml  was  tested  for  cytotoxic (18-h  51Cr-release  assay)  and 
cytostatic  (48-h  [3H]TdR-incorporation  assay)  effects  on  U937  cells,  and  for 
inhibition of colony formation by early and late CFU-GM precursor cells, in the 
presence or absence of 1,000 U/ml of rIFN-3' (Fig. 7). TNF induced a significant 
and dose-dependent cytotoxic effect on U937 cells in the range of concentrations 
tested, and the effect was increased by the presence of rlFN-'y. IFN-y alone was 
not  cytotoxic for  U937  cells.  Percent inhibition  of [3H]TdR  incorporation  at 
both 24 (not shown) and 48 h (Fig. 7) was higher than percent 5~Cr release at 18 
h, but most of the decreased incorporation of [3H]TdR was probably due to cell 1522  NATURAL  KILLER 
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FIGURE 6,  Gel filtration (A) and anion-exchange chromatography (B) of NKCF-containing 
supernatant produced by B73.1 ÷ PBL induced with K562 cells. Separations were performed 
as described using an FPLC apparatus and a Superose 12 column for gel filtration, or a Mono 
Q  column for anion-exchange chromatography. Each fraction was tested for cytotoxic activity 
(O) on L-929 cells and for NKCF activity (0) on U937 target cells (50% final concentration), 
TABLE  IV 
Effect of mAb LTB and TNFD on NKCF and NK-CIA Activity 
N umber of  mAb added* 
rlFN-3' 
Activity  Target cells  Inducer cells  superna-  (1,000 U/ml) 
tested  tants tested  None  LTB  TNFD 
NKCF  U937 
NK-CIA  CFU-GM (late) 
NK-CIA  ('FU-GM (early) 
K562  6  -  51.4 ±  23.2  $  49.1  ±  22.8  5.9 ±  7.4 
K562  6  -  -1.3  ±  3.9  -1.5  _  2.8  -0.7  ±  3.1 
K562  6  +  38.5 ±  22.8  39.7 ±  19.9  -6.7  ±  12.6 
Bone marrow  4  -  -1.5  ±  3.1  0.5 ±  1.7  -1.8  ±  2.4 
Bone marrow  4  +  28.5 ±  10.5  29.8 ±  5.6  -17.7  +  6.4 
K562  6  -  39.5 _  18.3  40.2 ±  15.3  3.7 +  6.6 
K562  6  +  40.2 ±  18.8  37.5 ±  16.2  2.7 ±  6,1 
Bone marrow  4  -  53.0 +  9.1  50.0 -  12.2  5.8 ±  5.9 
Bone marrow  4  +  46.5 ±  17.5  46.0 ±  16.1  -0.3  ±  0.6 
Supernatant  fluids,  obtained  fl'om  NK-enricbed  PBL  incubated  for  6  h  with  the  indicated  inducer  cells,  were  tested  for  NKCF 
activity and for NK-CIA activity on the indicated target cells, as described. 
* Supernatant  fluids were incubated  for 6  h  at  4°C with the indicated  mAb (5 #g]ml) before being tested  for  NKCF and NK-CIA 
activity. 
* Values indicate percent 5]Cr release (N KCF) or percent colony inhibition (NK-CIA) (mean ±  SD). Number of colonies (four separate 
experiments, mean +  SD) was: CFU-GM (late),  160.2 ±  29.6; CFU-GM (late),  1,000 U/ml rIFN-%  123.1  ±  36.0; CFU-GM (late), 5 
ug/ml  LTB,  152  -+ 42.5,  CFU-GM  (late),  5  #g/ml TNFD,  150,5  ±  33.4;  CFU-GM (early),  65.5  ±  10.1;  CFU-GM  (early),  1,000 
U/nd rlFN-% 65.3 ±  11.9; CFU-GM (early), 5 ~g/ml LTB, 65.7 ±  10.0; CFU-GM (early), 5 ,ug/ml TNFD,  65.3 ±  9.5, DEGLIANTONI  ET  AL.  1523 
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FIGURE  7.  Effect of rTNF on U937  cells and on CFU-GM colonies. Recombinant TNF at 
the indicated concentrations was tested on U937  target cells in (A) a  18-h 51Cr-release assay, 
and (B) a 48-h [SH]TdR incorporation assay, or was tested for its ability to inhibit (C) late (day 
7) CFU-GM colonies and (D) early (day 14) CFU-GM colonies, in the presence (0) or absence 
(O) of 1,000  U/ml of rlFN-3,. Number of colonies per  10 ~ bone marrow cells was: late CFU- 
GM,  183.7 _+ 1.7; late CFU-GM, 1,000 U/ml IFN-y, 92.3 +  2.7; early CFU-GM, 68.0 +  12.2; 
early GFU-GM,  1,000  U/ml of rIFN-3', 62.0 4- 7.3. 
death. A  similar inhibition of [3H]TdR uptake, but a  much lower 51Cr release, 
was observed on other myeloid cell lines, suggesting a predominantly cytostatic 
effect of TNF on those lines (not shown). The presence of 1,000 U/ml of rIFN- 
3'  alone resulted in  50%  inhibition  of [3H]TdR  incorporation, and induced a 
synergistic inhibition of [3H]TdR in conjunction with rTNF (Fig. 7). Formation 
of colonies by late (day 7) CFU-GM  precursor cells was inhibited by doses of 
rTNF ---4 U/ml, and in the presence of 1,000  U/mi of IFN-y, by doses ___0.25 
U/ml.  Formation  of colonies by  early (day  14)  CFU-GM  precursor cells was 
inhibited by doses of rTNF >-0.25  U/ml, and in the presence of 1,000 U/ml of 
IFN-3,, by doses >-0.06 U/ml. 1524  NATURAL  KILLER  CELL-DERIVED  COLONY-INHIBITING  FACTOR 
Discussion 
In this study, we have compared the factor responsible for the activity of NK- 
CIA-containing supernatants wih NKCF, and on the basis of functional, biochem- 
ical, and antigenic similarities, have identified the factor responsible for NK-CIA 
as  NKCF.  All  supernatants  containing  NK-CIA  also  contained  NKCF,  and  a 
highly  significant  positive  correlation  between  the  two  activities  was  demon- 
strated.  Previous studies (5,  32) have identified  NK cells as the  human  NKCF 
producer  cells  on  the  basis  of separation  of PBL  on  a  discontinuous  Percoll 
gradient.  However, because NK cell-enriched fractions on Percoll gradients are 
always contaminated  with  cell  types other  than  NK,  the presence of cells that 
produce a  given  lympbokine in  light-density  PBL preparations  is not sufficient 
to identify NK cells as the producers.  The  use of mAb has made it possible to 
distinguish and separate NK cells from the cells that produce IFN-o~ upon virus 
infection, and that copurify with NK cells on Percoll gradients (33). In this study, 
we  used  PBL  preparations  highly  enriched  for  cells  with  NK  activity  and 
obtained, using anti-NK cell-specific antibodies (B73.1 and N901), and a series 
of antilymphocyte  antibodies  reacting  with  antigens  present  or  absent  on  a 
proportion  of mature  NK cells. Results of all  cell separation  experiments were 
consistent, allowing the unambiguous identification of the cells producing NKCF 
as PBL bearing all and only the known surface markers of cytotoxic NK cells. 
IFN-treatment  of PBL enhances  both  NKCF and  NK-CIA production.  The 
same cell types, i.e.,  NK-sensitive cell lines and bone marrow ceils enriched for 
HLA-DR  ÷ precursor cells, induce NK ceils to produce both NK-CIA and NKCF. 
Similarly,  these same cell  types absorb both  NK-CIA and  NKCF activity from 
PBL supernatants.  The activity of NK-CIA and NKCF, and the ability of K562 
cells to absorb them are both blocked by D-mannose-6-phosphate.  Both NK-CIA 
and NKCF are inactivated by incubation at 37°C for 48 h. 
An 80 kD factor has been described recently (19) that is produced by a T  cell 
hybrid  line,  and  that  inhibits  bone marrow colony formation.  Unlike  NK-CIA 
and NKCF, this factor is specifically cytotoxic for HLA-DR  + cell lines, independ- 
ent of their sensitivity to NK cells, and its effect is prevented by anti-HLA-DR 
mAb (19, 34). NK-CIA can be distinguished from other factors mediating colony- 
inhibiting activity, such as prostaglandin  E, lactoferrin,  and acidic isoferritin on 
the  basis  of different  molecular  mass,  different  producer  ceils,  and  different 
mechanisms of inhibition. 
The absence of antiviral  activity in supernatant  fluids containing  strong NK- 
CIA  activity,  and  the  inability  of antibodies  against  IFN-oe  and  -3'  to  block 
inhibition of hematopoietic colonies by NK-CIA exclude the possibility that IFN 
accounts for the inhibition.  The inhibitory effect of IFN-c~ and -/3 on CFU-GM 
we observed using homogeneous  IFN preparations  is consistent  with  previous 
reports (16,  17).  However, unlike recent reports with natural IFN-y (17, 35), we 
find little or no inhibition  of CFU-GM colonies by rIFN-7, even at doses up to 
1,000 U/ml. This result does not rest in loss of activity of the IFN-3, preparation 
used, as repeated  controls indicated  intact  antiviral  activity, and  the ability to 
induce or enhance  HLA-DR antigen  expression on sensitive cell lines.  In other 
studies  (17,  35),  anti-lFN-7  mAb  blocked the  inhibition  of colony formation, 
and on this basis, IFN-y was identified as the colony-inhibiting activity contained DEGL1ANTONI ET  AL.  1525 
in  the  supernatant  fluid  of phytohemagglutinin-stimulated  human  PBL  (35). 
However, IFN-3, has a  strong synergistic effect with  LT in  preventing  growth 
inhibition  of various cell  lines  (36,  37);  the  effect of IFN-3,  is  probably more 
dramatic  than  that  previously described for IFN-o~ (11),  and  a  mixture  of LT 
and IFN-'y can completely prevent growth of cell lines that are not sensitive to 
the growth-inhibiting  activity of LT or IFN-7 alone.  LT are common contami- 
nants of purified preparations of natural  IFN-'y (36). We have evidence that the 
inhibition  of colony formation by the supernatant  fluid of phytohemagglutinin- 
stimulated  PBL is due to the synergistic action of LT and IFN-3, (M.  Murphy, 
manuscript  in  preparation).  Thus  it  is  possible  that  contaminant  LT  in  the 
purified  preparations  of  IFN-3,  are  responsible  for  the  inhibition  of colony 
formation, and that anti-IFN-3, antibodies prevent this inhibition  by abrogating 
the  synergistic  effect of the  two lymphokines.  As  suggested  in  a  recent  study 
(38),  it  is also possible that  IFN-3,  acts  only indirectly  on  the  precursor  cells, 
through  activation  of other  cell  types,  such  as  NK  cells,  T  cells,  or  mature 
granulocytes. These cell types may not be present in our bone marrow samples 
because of the low initial  contamination  with peripheral  blood ceils (NK and T 
cells), and  because mature  granulocytes are depleted on  F/H gradients.  Alter- 
natively, as suggested by studies (39) on  murine  bone marrow  precursor cells, 
the discordant results on the effects of IFN-3, might be due to the use of different 
types or different concentrations of CSF. 
Our data  indicate that  IFN-3,,  similar to the effect described for LT on cell 
lines (36, 37), has a strong synergistic effect with NK-CIA. Whereas NK-CIA in 
the absence of IFN-3, is active only on early myeioid colony precursors, it becomes 
highly effective on late GM precursor cells, which are nonresponsive to NK-CIA 
alone, when IFN-3, is present during the culture period. Because the activity of 
NK-CIA is lost after 2 d of culture at 37°C, and NK-C1A and IFN--y were added 
simultaneously to the cultures, IFN-"/must act on the GM precursor cells within 
the first 48 h  of culture.  The  inability of NK-CIA to affect late CFU-GM may 
rest in the loss of the receptors for NK-CIA during maturation of GM precursor 
cells. IFN-"r, on the other hand,  might induce the expression of these receptors. 
It is impossible, at present,  to determine whether this effect of IFN-3, is linked 
to its ability to induce HLA-DR antigen expression and monocytic differentiation 
on  immature  myeloid  cells,  but  a  direct  effect  on  HLA-DR  antigens  seems 
unlikely, due to the independence of NKCF activity and HLA-DR expression on 
target cells. The synergistic effect of IFN-3, and NK-CIA is of particular interest 
because NK cells are also efficient producers of IFN-3,, for example, in response 
to interleukin  2 (30).  IFN-y produced by NK or T  cells induces differentiation 
of immature myeloid cells (40) and B cells (41), and is a potent activator of cells 
such  as  macrophages  (42)  and  neutropbils  (43  and  our  unpublished  results), 
which  are  involved in  the  regulation  of hematopoiesis and  immune  responses 
through secretion of both stimulating and suppressing factors. 
The NK-CIA-containing supernatants contain <1-8 cytotoxin units, as assayed 
on  L-929 cells.  NKCF and  NK-CIA activities coelute with  the  L  cell cytotoxic 
activity  from  gel  filtration  and  anion-exchange  columns.  Also,  the  molecules 
mediating the three activities fail to bind to a lentil lectin-Sepharose column (not 
shown).  A  series of soluble factors  has  been  described that  exert cytotoxic or 1526  NATURAL  KILLER  CELL-DERIVED  COLONY-INHIBITING FACTOR 
cytostatic activity on hemopoietic cell lines or bone marrow cells. Classes of LT 
had been defined based on differing molecular mass (44),  but recent evidence 
(36) suggests that the higher molecular mass forms observed under nondenatur- 
ing  conditions  are  oligomers of the  two basic forms,  because sodium  dodecyl 
sulfate gel electrophoresis reveals only a 25 and a  20 kD form of pure LT (36). 
NKCF  elutes  upon  gel  filtration  in  two  peaks  of activity  that  may  represent 
different molecules or aggregates (dimers?) of a  single molecule of 15-20  kD. 
However, unlike NKCF (12), the 20 and the 25 kD monomeric forms of LT are 
not shown  under  nondenaturing  conditions.  A  transient  and  unstable peak  of 
LT activity of 10-15 kD (LT) has also been reported, but its molecular mass is 
lower than  that noted for NKCF or NK-CIA (44).  Under our separation condi- 
tions,  LT,  produced by mitogenic  stimulation  of peripheral  blood T  cells (44) 
and by phorbol ester stimulation  of B cell lines (45), elutes in gel filtration  as a 
major peak of 60 kD, and binds to lentil lectin columns and B cell-derived LT 
elutes from anion-exchange columns at a lower molarity than NKCF. 
TNF,  another  cytotoxin  produced  by leukocytes, has  been  characterized  in 
the serum of endotoxin-treated rabbits as a 68 kD molecule on sodium dodecyl 
sulfate  (SDS)  electrophoresis  (46).  TNF  produced  by  human  monocytes and 
myeloid cell  lines  resolves as a  30  kD peak  by gel  filtration,  and  as a  17  kD 
species on SDS gels (14,  15, and J. Vilcek, personal communication). Tbe cDNA 
for human TNF, cloned from HL-60 cells, encodes a protein of 156 amino acids 
with a calculated molecular weight of 17,356, with no N-glycosylation sites (14, 
15).  The TNF sequence shows 28%  homology with the LT sequence (13,  14). 
The biochemical characteristics of NKCF/NK-CIA and of the cytotoxin present 
in  these  preparations  are  not  inconsistent  with  those  reported  for  monocyte- 
derived TNF. The presence of the activity in the 15-20 kD peak in gel filtration 
could  be  due  to  the  presence  of a  monomeric  form  found  in  NK-derived 
supernatant  fluids, but not found in  the  monocyte-derived supernatant.  Alter- 
natively, the low molecular mass peak could be due to a hydrophobic interaction 
with  the  matrix  of the  FPLC  columns  used  in  our  separations,  whereas  such 
interaction might not occur with conventional gel filtration columns. Preliminary 
evidence suggesting the identification  of NKCF as TNF has been reported (47) 
based on the ability of anti-TNF  mAb to block NKCF activity (47).  We tested 
both anti-LT and anti-TNF for their ability to block NKCF and NK-CIA activity 
ill  our  supernatant  fluid.  Only  anti-TNF  antibodies  completely  blocked  the 
cytotoxic effect of several supernatants  on U937 target cells, and blocked their 
ability  to  inhibit  CFU-GM.  The  inhibition  of  early  GM  precursor  cells  by 
supernatants alone, and the inhibition of late GM precursor cells by supernatants 
plus rlFN-3, were both blocked by the anti-TNF antibody. These results suggest 
the possibility that  NK cells, in  response to target cell  lines or immature  bone 
marrow cells, produce TN F. This possibility is supported by the observation that 
purified rTNF is able to mediate NKCF and NK-CIA type activity in a range of 
concentrations corresponding to the titer of cytotoxins present in the NK cell- 
derived supernatant, as measured on L-929 cells. However, in light of the partial 
sequence homology between  LT and  TNF,  and  the  existence of lymphokines 
such as IFN that represent a group of homologous and only partially antigenically 
similar  molecules,  the  reactivity  of one  mAb with  both  TNF  and  NKCF/NK- DEGLIANTON! ET  AL.  1527 
CIA might  not constitute definitive evidence for the identification  of the cyto- 
toxin produced by NK cells with the TNF produced by monocytes. This identi- 
fication  will  require  detailed  comparative biochemical and antigenic  studies of 
the cytotoxins produced by the different cell types. 
Summary 
We characterize  the  natural  killer  (NK)  cell  colony-inhibiting  activity (CIA) 
produced in supernatants from cultures of human peripheral blood lymphocytes 
(PBL) with NK-sensitive target cell lines, and study its relationship with NK cell- 
derived cytotoxic factor (NKCF).  Using monoclonal  antibodies  (mAb) specific 
for NK cells or other lymphocyte populations,  we unambiguously identify NK 
cells  as  the  only  PBL  subset  able  to  produce  both  NKCF  and  NK-CIA.  We 
present  functional  and  biochemical  data  suggesting  that  NKCF  and  NK-CIA 
represent  the same molecule:  (a) a  highly significant  positive correlation  exists 
between  the  quantity  of  NKCF  and  NK-CIA  in  supernatants  independently 
produced by different PBL subsets; (b) both NK-CIA and NKCF are induced by 
culture of PBL with N K-sensitive, but not with N K-insensitive cell lines, and with 
HLA-DR  + bone marrow cells; (c) both NKCF and NK-CIA are absorbed on the 
same cell  lines or bone marrow  cell types; (d)  the  two activities coelute in  the 
same gel filtration  fractions; (e) D-mannose-6-phosphate  blocks both NKCF and 
NK-CIA  activity,  and  prevents  their  absorption  by  K562  cells;  and  (f)  both 
NKCF and NK-CIA activity are lost after 2 d at 37°C. 
The  NK-CIA-containing  preparations  are  devoid  of antiviral  activity,  and 
antiinterferon  (anti-IFN) antibodies do not block the inhibitory activity of NK- 
CIA. The effect of NK-CIA on day 14 (early) colony-forming units of granulo- 
cytes and  macrophages  (CFU-GM)  is  synergistic  with  that  of IFN-y,  and  this 
synergy is also evident on day 7 (late) CFU-GM growth.  A combination of NK- 
CIA and IFN-3, suppresses late CFU-GM, at concentrations of the two lympho- 
kines  that  are  completely  ineffective  when  used  independently.  No  synergy 
between NK-CIA and IFN-a or -/3 was observed, due to a direct inhibitory effect 
of these two IFN types on late CFU-GM. Antibodies specific for tumor necrosis 
factor (TNF), but not those specific for lymphotoxins, inhibit both NK-CIA and 
NKCF activity in  the  NK cell-derived supernatant.  Recombinant TNF,  in  the 
range of concentrations corresponding to that of the cytotoxic activity on L-929 
cells present  in  supernatants,  mediated  both  NKCF and  NK-CIA activity. To- 
gether,  our data  suggest that  the  molecules responsible for both the  cytotoxic 
effect of NK cell  supernatants  on  NK-sensitive cell  lines and  the  cytotoxic or 
cytostatic effect of the  same supernatants  on  bone  marrow  cells are  identical, 
and that these molecules are antigenically, functionally, and biochemically similar 
to or identical  with the TNF produced by human  monocytes and  myeloid cell 
lines. 
We thank M. Shade for technical  assistance, M. Hoffman for editing,  and M. Kaplan for 
typing the manuscript. 
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